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Introduction to Comment
Biomedical research is now a field not only opens to the
gathering of medical data on diagnostic tests, epidemic research
and disease prevention and cure. The purpose of biomedical
research is now properly changed to the application modern
methods of scientific sophistication whereby operations research,
statistical analytics and analysis and data management often
referred to as “Data Science” and for marketing purposes “Big
Data.”Research methods are now everywhere one sees from the
production of most automotive parts to the check-out lines at most
supermarkets and the design of seating arrangement to maximize
cash inflow on aircraft. Not all satisfy all users of technological
improvement but they are everywhere to satisfy the desires of the
decision makers whose goals vary but often provide satisfaction to
them. In the medical sciences, we observe trends in the direction
of great changes in patient care and quicker methods for decision
purposes. We often refer to this as automation but it is the
advances in computer technologies that drive this mechanization
of seemingly simple but technological advanced tasks to streamline
patient care methodologies. The growth of these technologies in
the future will speed up by breakthroughs in artificial intelligence
which will continue the mechanization of tasks improve the
quality of disease control, production of new pharmaceuticals,
intensive care improvement, disease and epidemic prevention and
water pollution and treatments after horrific storms which bring
problems to keeping water pure, available and easy to transport to
areas having great difficulties handling the aftermath of destructive
environment conditions. Artificial Intelligence (AI) includes the
leadership in Forensic Science Laboratories; Forensic Laboratory
Key Business Metrics and Cost–Benefit Analyses; Laboratory
Excellence and Ethics: An Essential Association; Laboratory
Excellence and Ethics: An Essential Association; ISO Accreditation
Implementation: A Framework to Implement a Quality and Writing
Policies and Procedures.

A Simple Example of Pharmaceutical Testing
New pharmaceutical testing is a subject matter where a new
cure for a disease is compared with two sample independently
drawn where one group is given the experimental drug and second
sample is given a placebo, a substance containing no medicinal
value. Scientific testing requires the researcher to determine if there
is a statistically scientific difference in the result of the experiment
and furthermore the experiment drug produces better result and
often how much better. Medical controls are often implement in
order that the two independently drawn samples differ only with
respect to whether the sample differs only by which pill is taken by
the patient. The problem is whether the sample are large enough
to draw scientific conclusions or the groups are dissimilar in
other ways that can affect the final curative results. Furthermore,
more scientific and sophisticated analyses could be employed that
explain real differences when they occur. Multivariate statistical
methods could be employed to examine the results which would
lead analysts to quicker and better conclusion. In addition, data
science and AI will produce the same results without human
interference which enable much faster certainty in the results and
bring new drugs to market at an exponentially faster pace.

Conclusion

The previous example and discussion will lead to great benefits
for society. The above commentary leads to medical researchers
rethinking their methodology, goal and purpose. The blending of
intelligent (AI) software and comprehensive data analytics will
eventually move health care analysts from the task of interpreting
results to have protocols produced for them. Intelligent software
will blend seamlessly with a decision maker’s operations insights
and produce a unique domain expertise to create better analytical
conclusions in the world we live in and certainly after horrendous
climatic events.
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